FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

The BioMimics 3D stent, whose shape mimics the helical geometry of human vasculature, has received premarket approval from the US Food and Drug Administration (FDA), device manufacturer Veryan Medical announced yesterday.

BioMimics 3D is now approved in the United States for the treatment of symptomatic de novo or restenotic lesions in the native superficial femoral artery and/or proximal popliteal artery. Based on the MIMICS randomized controlled trial, the device received CE Mark approval 6 years ago.

The FDA’s regulatory decision is largely based on results of MIMICS-2, an IDE study of 271 symptomatic patients with PAD (mean age 68.4 years; 66.4% men) conducted at 47 centers in the United States, Germany, and Japan.

Safety, defined as freedom from major adverse events (death, major amputation, or clinically driven TLR) through 30 days, was 99.6%, exceeding the performance goal of greater than 88%. At 12 months, freedom from clinically driven TLR was 88%, with most events occurring after 6 months, and freedom from loss of primary patency was 83%.

‘Swirling Blood Flow’

“BioMimics 3D represents an innovative approach to the requirement for durable support for the arterial lumen after intervention,” according to a press release from Veryan Medical. “The helical center-line stent is designed to not only promote swirling blood flow but also to accommodate the complex biomechanical challenge associated with stenting this anatomically mobile artery.”

When presenting the results of MIMICS-2 at the 2018 International Symposium on Endovascular Therapy this February, co-principal investigator Timothy M. Sullivan, MD (Minneapolis Heart Institute, MN), explained the mechanics of BioMimics 3D. “Nonplanar curvature in arterial systems promotes swirling flow, which increases wall shear stress, which is not only atheroprotective but . . . protective against neointimal hyperplasia following intervention,” he said. Due to its shape, BioMimics 3D similarly affects blood flow. With improved biomechanical performance, the device may be especially useful “in hostile arterial environments like the distal SFA,” Sullivan suggested.

Photo Credit: Veryan Medical